Top

Cancer Chemotherapy and Pharmacology

Published in:

01-11-2016 | Original Article

Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats

Authors: Alexandre Iarkov, Doreen Appunn, Valentina Echeverria

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2016

Abstract

Purpose

Most cancer patients treated with systemic adjuvant chemotherapy endure long-lasting side effects including decrease in concentration, forgetfulness and slower thinking, which are globally termed “chemobrain.” Cotinine, the main derivative of nicotine, improved visual and spatial working memory and decreased depressive-like behavior in an animal model of chemotherapy-induced cognitive impairment.

Methods

In this study, we investigated the effect of cotinine on weight gain, locomotor activity, cognitive abilities and depressive-like behavior in rats treated with the chemotherapy mix, cyclophosphamide, methotrexate and 5-fluorouracil. Locomotor activity and depressive-like behavior were assessed using the rotarod and Porsolt’s tests, respectively. Changes in cognitive abilities were determined using the novel place recognition test.

Results

Female rats treated with cotinine after chemotherapy, recovered weight faster, showed superior cognitive abilities and lower levels of depressive-like behavior than chemotherapy, vehicle-treated rats.

Conclusions

This evidence suggests that treatment with cotinine may facilitate the recovery and diminish the cognitive consequences of chemotherapy.

Belcher EC-GK, Desantis C, Edwards B, Ferlay J, Forman D, Grey N, Harford J, Kramer J, McMikel A, McNeal B, O’Brien M, Pace L, Parkin M, Robbins A, Sankaranarayanan R, Sitas F, Slona R, Sullivan K, Wagner D, Ward E (2011) Global cancer facts and Figures, 2nd edn. American Cancer Society, Atlanta

de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, Boven E, Schagen SB (2011) Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 32(8):1206–1219CrossRefPubMed

Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian V, Limoli CL (2012) Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res 18(7):1954–1965CrossRefPubMed

Myers JS (2009) Chemotherapy-related cognitive impairment. Clin J Oncol Nurs 13(4):413–421CrossRefPubMed

Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M (2010) It’s not over when it’s over: long-term symptoms in cancer survivors–a systematic review. Int J Psychiatry Med 40(2):163–181CrossRefPubMed

Seliktar N, Polek C, Brooks A, Hardie T (2015) Cognition in breast cancer survivors: hormones versus depression. Psychooncology 24(4):402–407. doi:10.1002/pon.3602 CrossRefPubMed

Joly F, Rigal O, Noal S, Giffard B (2011) Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 20(12):1251–1258CrossRefPubMed

Fardell JE, Vardy J, Johnston IN, Winocur G (2011) Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther 90(3):366–376. doi:10.1038/clpt.2011.112 CrossRefPubMed

Brauch H, Mürdter TE, Eichelbaum M, Schwab M (2009) Pharmacogenomics of tamoxifen therapy. Clin Chem 55(10):1770–1782. doi:10.1373/clinchem.2008.121756 CrossRefPubMed

10.

Fouladi M, Chintagumpala M, Laningham FH, Ashley D, Kellie SJ, Langston JW, McCluggage CW, Woo S, Kocak M, Krull K, Kun LE, Mulhern RK, Gajjar A (2004) White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 22(22):4551–4560. doi:10.1200/JCO.2004.03.058 CrossRefPubMed

11.

Choi SM, Lee SH, Yang YS, Kim BC, Kim MK, Cho KH (2001) 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci 16(3):328–334. doi:10.3346/jkms.2001.16.3.328 CrossRefPubMedPubMedCentral

12.

Koppelmans V, de Groot M, de Ruiter MB, Boogerd W, Seynaeve C, Vernooij MW, Niessen WJ, Schagen SB, Breteler MM (2014) Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp 35(3):889–899. doi:10.1002/hbm.22221 CrossRefPubMed

13.

Raffa RB (2011) Cancer ‘survivor-care’: I. the alpha7 nAChR as potential target for chemotherapy-related cognitive impairment. J Clin Pharm Ther 36(4):437–445. doi:10.1111/j.1365-2710.2010.01208.x CrossRefPubMed

14.

Terry AV Jr, Hernandez CM, Hohnadel EJ, Bouchard KP, Buccafusco JJ (2005) Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev 11(3):229–252CrossRefPubMed

15.

Zeitlin R, Patel S, Solomon R, Tran J, Weeber EJ, Echeverria V (2012) Cotinine enhances the extinction of contextual fear memory and reduces anxiety after fear conditioning. Behav Brain Res 228(2):284–293CrossRefPubMed

16.

Grizzell JA, Mullins M, Iarkov A, Rohani A, Charry LC, Echeverria V (2014) Cotinine reduces depressive-like behavior and hippocampal vascular endothelial growth factor downregulation after forced swim stress in mice. Behav Neurosci 128(6):713–721. doi:10.1037/bne0000021 CrossRefPubMed

17.

Levin ED (2012) alpha7-Nicotinic receptors and cognition. Curr Drug Targets 13(5):602–606CrossRefPubMed

18.

Rubboli F, Court JA, Sala C, Morris C, Perry E, Clementi F (1994) Distribution of neuronal nicotinic receptor subunits in human brain. Neurochem Int 25(1):69–71CrossRefPubMed

19.

Grizzell JA, Iarkov A, Holmes R, Mori T, Echeverria V (2014) Cotinine reduces depressive-like behavior, working memory deficits, and synaptic loss associated with chronic stress in mice. Behav Brain Res 268:55–65. doi:10.1016/j.bbr.2014.03.047 CrossRefPubMed

20.

Macleod JE, DeLeo JA, Hickey WF, Ahles TA, Saykin AJ, Bucci DJ (2007) Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 181(1):168–172CrossRefPubMedPubMedCentral

21.

Lyons L, ElBeltagy M, Umka J, Markwick R, Startin C, Bennett G, Wigmore P (2011) Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology 215(1):105–115. doi:10.1007/s00213-010-2122-2 CrossRefPubMed

22.

Lyons L, ElBeltagy M, Bennett G, Wigmore P (2012) Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS ONE 7(1):e30010. doi:10.1371/journal.pone.0030010 CrossRefPubMedPubMedCentral

23.

Briones TL, Woods J (2011) Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 12:124CrossRefPubMedPubMedCentral

24.

Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85(3):640–650CrossRefPubMed

25.

Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Schagen SB (2013) Late effects of adjuvant chemotherapy for adult onset non-CNS cancer; cognitive impairment, brain structure and risk of dementia. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2013.04.002 PubMed

26.

Echeverria V, Zeitlin R (2012) Cotinine: a potential new therapeutic agent against Alzheimer’s disease. CNS Neurosci Ther 18(7):517–523CrossRefPubMed

27.

Hatsukami DK, Grillo M, Pentel PR, Oncken C, Bliss R (1997) Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol Biochem Behav 57(4):643–650CrossRefPubMed

28.

Terry AV Jr, Buccafusco JJ, Schade RF, Vandenhuerk L, Callahan PM, Beck WD, Hutchings EJ, Chapman JM, Li P, Bartlett MG (2012) The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem Pharmacol 83(7):941–951CrossRefPubMedPubMedCentral

29.

Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31(1):47–59CrossRefPubMed

30.

Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229(2):327–336PubMed

31.

Castagne V, Moser P, Roux S, Porsolt RD (2010) Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci 49:5.8.1–5.8.14

32.

Jones BJ, Roberts DJ (1968) A rotarod suitable for quantitative measurements of motor incoordination in naive mice. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 259(2):211CrossRefPubMed

33.

Ayres A, Hoon PW, Franzoni JB, Matheny KB, Cotanch PH, Takayanagi S (1994) Influence of mood and adjustment to cancer on compliance with chemotherapy among breast cancer patients. J Psychosom Res 38(5):393–402CrossRefPubMed

34.

Fremouw T, Fessler CL, Ferguson RJ, Burguete Y (2012) Preserved learning and memory in mice following chemotherapy: 5-Fluorouracil and doxorubicin single agent treatment, doxorubicin-cyclophosphamide combination treatment. Behav Brain Res 226(1):154–162. doi:10.1016/j.bbr.2011.09.013 CrossRefPubMed

35.

Fardell JE, Vardy J, Johnston IN (2013) The short and long term effects of docetaxel chemotherapy on rodent object recognition and spatial reference memory. Life Sci. doi:10.1016/j.lfs.2013.05.006 PubMed

36.

Grizzell JA, Echeverria V (2015) New insights into the mechanisms of action of cotinine and its distinctive effects from nicotine. Neurochem Res 40:2032–2046CrossRefPubMed

37.

Matsunaga M, Isowa T, Yamakawa K, Fukuyama S, Shinoda J, Yamada J, Ohira H (2014) Genetic variations in the human cannabinoid receptor gene are associated with happiness. PLoS ONE 9(4):e93771. doi:10.1371/journal.pone.0093771 CrossRefPubMedPubMedCentral

38.

Rehani K, Scott DA, Renaud D, Hamza H, Williams LR, Wang H, Martin M (2008) Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim Biophys Acta 1783(3):375–382CrossRefPubMed

39.

J. GAO B-LA, J. M. CHAPMAN, D. BERTRAND, A. V. TERRY1; (2012) Neuroprotective effects of the nicotine metabolite, cotinine, and several structural analogs of cotinine Paper presented at the Society for Neuroscience, New Orleans

40.

Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH (2007) Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 97(2):279–287. doi:10.1093/toxsci/kfm060 CrossRefPubMed

41.

Doolittle DJ, Winegar R, Lee CK, Caldwell WS, Hayes AW, de Bethizy JD (1995) The genotoxic potential of nicotine and its major metabolites. Mutat Res 344(3–4):95–102CrossRefPubMed

42.

LaVoie EJ, Shigematsu A, Rivenson A, Mu B, Hoffmann D (1985) Evaluation of the effects of cotinine and nicotine-N’-oxides on the development of tumors in rats initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. J Nat Cancer Inst 75(6):1075–1081PubMed

43.

Barbieri RL, Gochberg J, Ryan KJ (1986) Nicotine, cotinine, and anabasine inhibit aromatase in human trophoblast in vitro. J Clin Invest 77(6):1727–1733CrossRefPubMedPubMedCentral

Title: Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats
Authors: Alexandre Iarkov
Doreen Appunn
Valentina Echeverria
Publication date: 01-11-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3161-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2016

Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma

Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors

Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia

A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer

Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience

Synthesis of polydopamine as a new and biocompatible coating of magnetic nanoparticles for delivery of doxorubicin in mouse breast adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer